The Six PCAC-Recommended Peptides: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon Pricing After the July 2026 Vote

On July 23 and 24, 2026, an FDA advisory panel said yes to six peptides. The Pharmacy Compounding Advisory Committee (PCAC) recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulks list. It rejected a seventh, emideltide (DSIP), by a 6-7 vote, and the margins on the winners were thin: 8-6 with one abstention for BPC-157 and KPV, 7-4 for Epitalon. Every yes vote went against written advice from FDA career scientists.

The vote did not make any of these peptides legal to compound. Two terms explain why. Section 503A covers state-licensed pharmacies that make a drug for one named patient with a prescription. Section 503B covers larger "outsourcing facilities" registered with the FDA that can compound in bulk without patient-specific prescriptions. Either kind can only use an unapproved ingredient that appears on the matching bulks list, the FDA's roster of allowed substances. A PCAC vote is advice, and the FDA still has to publish a proposed rule, take public comments, and issue a final rule. As of September 2, 2026, the FDA's 503A bulks list page (last updated May 14, 2026) lists none of the six, and no proposed rule has appeared. HHS Secretary Robert F. Kennedy Jr. has to sign off on any addition. The next PCAC peptide meeting, on five different peptides, is due before the end of February 2027. The White House named Dr. Heidi Overton as its FDA commissioner pick on August 18, and her Senate review is pending.

So the market looks much like it did in April. Telehealth programs still sell these peptides as compounded prescriptions. Prices run from $80 a vial plus a $39 visit at RxPepsDirect to $445 per eight-week cycle at Perfect B in Doral, Florida. Research vendors still sell "research-use-only" vials: powder with a not-for-human-use label and no prescription, from $35 (Bluum TB-500, 5 mg) to $130 (Evolve Epithalon, 50 mg). Hims & Hers, whose chief medical officer testified at the meeting, says it will not sell any of the six until the FDA finishes rulemaking. A July 28 vendor survey found research-vial prices per milligram unchanged by the vote. A few pages did move between our April guides and this check. BeyondMD's BPC-157/TB-500 capsule program went from $199 to $249. Bluum's TB-500 fell from $50 to $35, and we cannot tie either change to the vote.

How to read the tables. Each peptide section lists a telehealth or clinic program, a compounded price where a program publishes one, and research vendors. Compounded prices sit in a gray zone: the sellers describe 503A pharmacies filling patient-specific prescriptions, yet none of the six is on the 503A list. The individual guides carry more vendors and dosing detail: BPC-157, KPV, TB-500, MOTS-c, Semax and Selank, Epithalon, and the KLOW blend that packages KPV with BPC-157, TB-500, and GHK-Cu. For the legal mechanics of the vote, see The FDA Panel Voted Yes on BPC-157 and KPV. Compounding Is Still Not Legal Today.